Merve Süleyman1, Oğuzhan Serin1, Büşra Koçali1, Diclehan Orhan2, Elmas Ebru Yalçın3, Uğur Özçelik3, Mehmet Ceyhan4, Nural Kiper3, İlhan Tezcan5,6, Deniz Dogru3, Deniz Çağdaş7,8. 1. Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey. 2. Department of Pediatrics, Hacettepe University Medical School, Section of Pediatric Pathology, Ankara, Turkey. 3. Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University Medical School, Ankara, Turkey. 4. Department of Pediatric Infectious Diseases, Hacettepe University Medical School, Ankara, Turkey. 5. Department of Pediatrics, Division of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey. 6. Institute of Child Health, Department of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey. 7. Department of Pediatrics, Division of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey. deniz.ayvaz@hacettepe.edu.tr. 8. Institute of Child Health, Department of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey. deniz.ayvaz@hacettepe.edu.tr.
Abstract
OBJECTIVE: Granuloma etiology includes infections, vasculitis, chemicals, malignancies, lymphoproliferative disorders, and immunological diseases. We hypothesized that patients with granuloma have an underlying primary immunodeficiency disease (PIDD). PATIENTS AND METHODS: We retrospectively enrolled 82 patients with immunological evaluation among 294 biopsy-proven granuloma patients (0- to 20-year-old). At the same time frame, we followed up with 1910 patients in the same age group. RESULTS: Out of 82 patients, male/female ratio was 45/37. Median age at symptom onset was 5 years (28 days-17.4 years), age of granuloma at diagnosis was 8.6 years (36 days-19.4 years). Common symptoms at disease onset were fever (23.2%), lymphadenopathy (19.6%), abdominal pain (12.2%), and cough (12.2%). Granuloma was frequent in lymph nodes (26.8%), skin (19.5%), lung (13.4%), and bone (11%). Common infectious agents isolated were Mycobacterium spp. (23.2%) and EBV (4.9%). We document PIDD in 76.8% (63/82) of patients. 49.4% (40/81) of immunologically evaluated granuloma patients had hypogammaglobulinemia. Granuloma rate in pediatric PIDD was 3.3%(63/1910). Patients with multiple granulomas (n = 16) had a PIDD diagnosis. Lung involvement was three times more in PIDD. Brain involvement was only seen in PIDD. Fibroadipose tissue and liver involvement were more frequent in patients without documented PIDD and patients whose evaluation was not completed. The mortality rate in PIDD with granuloma was 15.9%, whereas there was no mortality in patients without PIDD. CONCLUSION: As documented here, even in a university hospital, the immunologic evaluation ratio is about one-third. We showed high PIDD frequency in children with granuloma, and higher mortality in PIDD with granuloma. Thus, an immunologic evaluation performed meticulously by immunologists is a must for accurate diagnosis and decision of individualized therapeutic options.
OBJECTIVE: Granuloma etiology includes infections, vasculitis, chemicals, malignancies, lymphoproliferative disorders, and immunological diseases. We hypothesized that patients with granuloma have an underlying primary immunodeficiency disease (PIDD). PATIENTS AND METHODS: We retrospectively enrolled 82 patients with immunological evaluation among 294 biopsy-proven granuloma patients (0- to 20-year-old). At the same time frame, we followed up with 1910 patients in the same age group. RESULTS: Out of 82 patients, male/female ratio was 45/37. Median age at symptom onset was 5 years (28 days-17.4 years), age of granuloma at diagnosis was 8.6 years (36 days-19.4 years). Common symptoms at disease onset were fever (23.2%), lymphadenopathy (19.6%), abdominal pain (12.2%), and cough (12.2%). Granuloma was frequent in lymph nodes (26.8%), skin (19.5%), lung (13.4%), and bone (11%). Common infectious agents isolated were Mycobacterium spp. (23.2%) and EBV (4.9%). We document PIDD in 76.8% (63/82) of patients. 49.4% (40/81) of immunologically evaluated granuloma patients had hypogammaglobulinemia. Granuloma rate in pediatric PIDD was 3.3%(63/1910). Patients with multiple granulomas (n = 16) had a PIDD diagnosis. Lung involvement was three times more in PIDD. Brain involvement was only seen in PIDD. Fibroadipose tissue and liver involvement were more frequent in patients without documented PIDD and patients whose evaluation was not completed. The mortality rate in PIDD with granuloma was 15.9%, whereas there was no mortality in patients without PIDD. CONCLUSION: As documented here, even in a university hospital, the immunologic evaluation ratio is about one-third. We showed high PIDD frequency in children with granuloma, and higher mortality in PIDD with granuloma. Thus, an immunologic evaluation performed meticulously by immunologists is a must for accurate diagnosis and decision of individualized therapeutic options.
Authors: E J H Schatorjé; E F A Gemen; G J A Driessen; J Leuvenink; R W N M van Hout; E de Vries Journal: Scand J Immunol Date: 2012-04 Impact factor: 3.487
Authors: C Bodemer; V Sauvage; N Mahlaoui; J Cheval; T Couderc; S Leclerc-Mercier; M Debré; I Pellier; L Gagnieur; S Fraitag; A Fischer; S Blanche; M Lecuit; M Eloit Journal: Clin Microbiol Infect Date: 2014-03-05 Impact factor: 8.067
Authors: William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Maria Isabel de Moraes-Pinto; Erika Ono; Elisângela C Santos-Valente; Liziane C Almeida; Paula Rosemberg de Andrade; Maria Isabel Saraiva Dinelli; Amélia M Nunes dos Santos; Reinaldo Salomão Journal: Mem Inst Oswaldo Cruz Date: 2014-11-21 Impact factor: 2.743
Authors: Stuart G Tangye; Waleed Al-Herz; Aziz Bousfiha; Talal Chatila; Charlotte Cunningham-Rundles; Amos Etzioni; Jose Luis Franco; Steven M Holland; Christoph Klein; Tomohiro Morio; Hans D Ochs; Eric Oksenhendler; Capucine Picard; Jennifer Puck; Troy R Torgerson; Jean-Laurent Casanova; Kathleen E Sullivan Journal: J Clin Immunol Date: 2020-01-17 Impact factor: 8.317